<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">35307230</PMID><DateCompleted><Year>2023</Year><Month>04</Month><Day>03</Day></DateCompleted><DateRevised><Year>2023</Year><Month>04</Month><Day>24</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1873-2518</ISSN><JournalIssue CitedMedium="Internet"><Volume>41 Suppl 1</Volume><Issue>Suppl 1</Issue><PubDate><Year>2023</Year><Month>Apr</Month><Day>06</Day></PubDate></JournalIssue><Title>Vaccine</Title><ISOAbbreviation>Vaccine</ISOAbbreviation></Journal><ArticleTitle>Enabling accelerated vaccine roll-out for Public Health Emergencies of International Concern (PHEICs): Novel Oral Polio Vaccine type 2 (nOPV2) experience.</ArticleTitle><Pagination><StartPage>A122</StartPage><EndPage>A127</EndPage><MedlinePgn>A122-A127</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.vaccine.2022.02.050</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0264-410X(22)00195-5</ELocationID><Abstract><AbstractText>To address the evolving risk of circulating vaccine-derived poliovirus type 2 (cVDPV2), Global Polio Eradication Initiative (GPEI) partners are working closely with countries to deploy an additional innovative tool for outbreak response - novel oral polio vaccine type 2 (nOPV2). The World Health Organization's (WHO) Prequalification program issued an Emergency Use Listing (EUL) recommendation for nOPV2 on 13 November 2020. The WHO's EUL procedure was created to assess and list unlicensed vaccines, therapeutics and diagnostics to enable their use in response to a Public Health Emergency of International Concern (PHEIC). nOPV2 was the first vaccine to receive an EUL, paving the way for other emergency vaccines. In this report, we summarise the pathway for nOPV2 roll-out under EUL.</AbstractText><CopyrightInformation>Copyright © 2022. Published by Elsevier Ltd.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Macklin</LastName><ForeName>Grace R</ForeName><Initials>GR</Initials><AffiliationInfo><Affiliation>London School of Hygiene and Tropical Medicine, London, United Kingdom; Polio Eradication, World Health Organisation, Geneva, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Peak</LastName><ForeName>Corey</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Bill and Melinda Gates Foundation, Seattle, Washington, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Eisenhawer</LastName><ForeName>Martin</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Polio Eradication, World Health Organisation, Geneva, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kurji</LastName><ForeName>Feyrouz</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>FDK Consulting LLC, Kirkland, Washington, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mach</LastName><ForeName>Ondrej</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>Polio Eradication, World Health Organisation, Geneva, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Konz</LastName><ForeName>John</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>PATH, Seattle, Washington, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gast</LastName><ForeName>Chris</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>PATH, Seattle, Washington, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bachtiar</LastName><ForeName>Novilia Sjafri</ForeName><Initials>NS</Initials><AffiliationInfo><Affiliation>Bio Farma, Bandung, Indonesia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bandyopadhyay</LastName><ForeName>Ananda S</ForeName><Initials>AS</Initials><AffiliationInfo><Affiliation>Bill and Melinda Gates Foundation, Seattle, Washington, United States. Electronic address: ananda.bandyopadhyay@gatesfoundation.org.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zipursky</LastName><ForeName>Simona</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Polio Eradication, World Health Organisation, Geneva, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><CollectiveName>nOPV2 Working Group</CollectiveName></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>001</GrantID><Acronym>WHO_</Acronym><Agency>World Health Organization</Agency><Country>International</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>03</Month><Day>17</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>Vaccine</MedlineTA><NlmUniqueID>8406899</NlmUniqueID><ISSNLinking>0264-410X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011055">Poliovirus Vaccine, Oral</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011634" MajorTopicYN="N">Public Health</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004630" MajorTopicYN="N">Emergencies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011055" MajorTopicYN="N">Poliovirus Vaccine, Oral</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017955" MajorTopicYN="Y">Poliovirus</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011051" MajorTopicYN="Y">Poliomyelitis</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014943" MajorTopicYN="N">Global Health</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D060740" MajorTopicYN="N">Disease Eradication</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Emergency use listing</Keyword><Keyword MajorTopicYN="N">Novel oral poliovirus vaccine</Keyword><Keyword MajorTopicYN="N">Poliovirus</Keyword><Keyword MajorTopicYN="N">Public health emergency of international concern</Keyword><Keyword MajorTopicYN="N">Vaccine</Keyword></KeywordList><CoiStatement>Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>8</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2022</Year><Month>1</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>2</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>4</Month><Day>3</Day><Hour>6</Hour><Minute>41</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>3</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>3</Month><Day>21</Day><Hour>5</Hour><Minute>32</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2023</Year><Month>4</Month><Day>6</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35307230</ArticleId><ArticleId IdType="pmc">PMC10109087</ArticleId><ArticleId IdType="doi">10.1016/j.vaccine.2022.02.050</ArticleId><ArticleId IdType="pii">S0264-410X(22)00195-5</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Sutter R.W., Kew O.M., Cochi S.L., Aylward R.B. Plotkin's Vaccines. Elsevier; 2018. Poliovirus vaccine–live; pp. 866–917.e16.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/B978-0-323-35761-6.00048-1</ArticleId></ArticleIdList></Reference><Reference><Citation>Kew O.M., Sutter R.W., de Gourville E.M., Dowdle W.R., Pallansch M.A. Vaccine-derived polioviruses and the endgame strategy for global polio eradication. Annu Rev Microbiol. 2005;59(1):587–635.</Citation><ArticleIdList><ArticleId IdType="pubmed">16153180</ArticleId></ArticleIdList></Reference><Reference><Citation>Macklin G.R., O’Reilly K.M., Grassly N.C., Edmunds W.J., Mach O., Santhana Gopala Krishnan R., et al. Evolving epidemiology of poliovirus serotype 2 following withdrawal of the serotype 2 oral poliovirus vaccine. Science. 2020;368(6489):401–405.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10805349</ArticleId><ArticleId IdType="pubmed">32193361</ArticleId></ArticleIdList></Reference><Reference><Citation>Macklin G.R., Grassly N.C., Sutter R.W., Mach O., Bandyopadhyay A.S., Edmunds W.J., et al. Vaccine schedules and the effect on humoral and intestinal immunity against poliovirus: a systematic review and network meta-analysis. Lancet Infect Dis. 2019;19(10):1121–1128.</Citation><ArticleIdList><ArticleId IdType="pubmed">31350192</ArticleId></ArticleIdList></Reference><Reference><Citation>Bandyopadhyay A.S., Macklin G.R. Final frontiers of the polio eradication endgame. Curr Opin Infect Dis. 2020;33(5):404–410.</Citation><ArticleIdList><ArticleId IdType="pubmed">32773500</ArticleId></ArticleIdList></Reference><Reference><Citation>Yeh M.T., Bujaki E., Dolan P.T., Smith M., Wahid R., Konz J., et al. Engineering the Live-Attenuated Polio Vaccine to Prevent Reversion to Virulence. Cell Host Microbe. 2020;27(5):736–751.e8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7566161</ArticleId><ArticleId IdType="pubmed">32330425</ArticleId></ArticleIdList></Reference><Reference><Citation>Konopka-Anstadt J.L., Campagnoli R., Vincent A., Shaw J., Wei L., Wynn N.T., et al. Development of a new oral poliovirus vaccine for the eradication end game using codon deoptimization. npj Vaccines. 2020;5(1) doi: 10.1038/s41541-020-0176-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41541-020-0176-7</ArticleId><ArticleId IdType="pmc">PMC7083942</ArticleId><ArticleId IdType="pubmed">32218998</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Damme P., De Coster I., Bandyopadhyay A.S., Revets H., Withanage K., De Smedt P., et al. The safety and immunogenicity of two novel live attenuated monovalent (serotype 2) oral poliovirus vaccines in healthy adults: a double-blind, single-centre phase 1 study. Lancet. 2019;394(10193):148–158.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6626986</ArticleId><ArticleId IdType="pubmed">31174831</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Damme P., Coster I.D., Bandyopadhyay A.S., Suykens L., Rudelsheim P., Neels P., et al. Poliopolis: pushing boundaries of scientific innovations for disease eradication. Future microbiology. 2019;14(15):1321–1330.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9186300</ArticleId><ArticleId IdType="pubmed">31482728</ArticleId></ArticleIdList></Reference><Reference><Citation>Brickley E.B., Connor R.I., Wieland-Alter W., Weiner J.A., Ackerman M.E., Arita M., et al. Intestinal antibody responses to two novel live attenuated type 2 oral poliovirus vaccines in healthy adults in Belgium. J Infect Dis. 2020</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9400418</ArticleId><ArticleId IdType="pubmed">33367918</ArticleId></ArticleIdList></Reference><Reference><Citation>De Coster I., Leroux-Roels I., Bandyopadhyay A.S., Gast C., Withanage K., Steenackers K., et al. Safety and immunogenicity of two novel type 2 oral poliovirus vaccine candidates compared with a monovalent type 2 oral poliovirus vaccine in healthy adults: two clinical trials. Lancet. 2021;397(10268):39–50.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7811203</ArticleId><ArticleId IdType="pubmed">33308429</ArticleId></ArticleIdList></Reference><Reference><Citation>Sáez-Llorens X., Bandyopadhyay A.S., Gast C., Leon T.D., DeAntonio R., Jimeno J., et al. Safety and immunogenicity of two novel type 2 oral poliovirus vaccine candidates compared with a monovalent type 2 oral poliovirus vaccine in children and infants: two clinical trials. Lancet. 2021;397(10268):27–38.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7811205</ArticleId><ArticleId IdType="pubmed">33308427</ArticleId></ArticleIdList></Reference><Reference><Citation>World Health Organisation. Emergency Use Listing Procedure, Version 9. Geneva, Switzerland: World Health Organisation; 2020. Available from: https://extranet.who.int/prequal/sites/default/files/documents/EUL_Procedure_Jan2020.pdf.</Citation></Reference><Reference><Citation>Zarocostas J. WHO keeps polio on the international health emergency list. Lancet. 2018;392(10163):2425. doi: 10.1016/S0140-6736(18)33115-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(18)33115-5</ArticleId><ArticleId IdType="pubmed">30527404</ArticleId></ArticleIdList></Reference><Reference><Citation>World Health Organisation. Roadmap for assessment of nOPV2 manufactured by PT Biofarma under the EUL procedure World Health Organisation; 2020. Available from: https://www.who.int/medicines/news/2020/roadmap-assessment-nOPV2.pdf?ua=1.</Citation></Reference><Reference><Citation>Famulare M., Chang S., Iber J., Zhao K., Adeniji J.A., Bukbuk D., et al. Sabin Vaccine Reversion in the Field: a Comprehensive Analysis of Sabin-Like Poliovirus Isolates in Nigeria. J Virol. 2016;90(1):317–331.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4702576</ArticleId><ArticleId IdType="pubmed">26468545</ArticleId></ArticleIdList></Reference><Reference><Citation>Taniuchi M., Famulare M., Zaman K., Uddin M.J., Upfill-Brown A.M., Ahmed T., et al. Community transmission of type 2 poliovirus after cessation of trivalent oral polio vaccine in Bangladesh: an open-label cluster-randomised trial and modelling study. Lancet Infect Dis. 2017;17(10):1069–1079.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5610141</ArticleId><ArticleId IdType="pubmed">28693854</ArticleId></ArticleIdList></Reference><Reference><Citation>Kroiss S.J., Ahmadzai M., Ahmed J., Alam M.M., Chabot-Couture G., Famulare M., et al. Assessing the sensitivity of the polio environmental surveillance system. PLoS One. 2018;13(12):e0208336.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6310268</ArticleId><ArticleId IdType="pubmed">30592720</ArticleId></ArticleIdList></Reference><Reference><Citation>Organization W.H. Meeting of the Strategic Advisory Group of Experts on Immunization, October 2020–conclusions and recommendations. Wkly Epidemiol Rec. 2020;95(48):585–607.</Citation></Reference><Reference><Citation>Organization WH. Meeting of the Strategic Advisory Group of Experts on Immunization, October 2021–conclusions and recommendations. Weekly Epidemiological Record [No 50] 2021;96:613–32.</Citation></Reference><Reference><Citation>World Health Organisation. Executive Board, 146th session, Agenda item 16.1 - Polio Eradication World Health Organisation: World Health Organisation; 2020. Available from: https://apps.who.int/gb/ebwha/pdf_files/EB146/B146(11)-en.pdf.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle>